Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

03,791 502,770 ------- ------- Total liabilities 3,984,394 3,913,569 --------- --------- Stockholders' equity: Common stock 26,653 26,653 Additional paid-in capital 273,296,804 270,988,157 Accumulated other comprehensive loss (754) (20,029) Deficit accumulated during the development stage (231,478,495) (224,974,507) ------------ ------------ Total stockholders' equity 41,844,208 46,020,274 ---------- ---------- Total liabilities and ----------- ----------- stockholders' equity $45,828,602 $49,933,843 =========== =========== VANDA PHARMACEUTICALS INC. (A Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Three Months Ended ------------------ March 31, March 31, 2009 2008 ---- ---- Cash flows from operating activities: Net loss $(6,503,988) $(19,196,129) Adjustments to reconcile net income to net cash used in operating activities: Depreciation and amortization 122,795 122,629 Stock-based compensation 2,308,64
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...charge their cell phones and other personal electr...y made by UC San Diego engineers could lead to car...ust this. , In recent research, published in A...essor in the UCSD Department of Mechanical and Aer...rk Hoefer, have found that artificially introduced...
(Date:11/19/2009)...swire/ -- Dr. Mate Hidvegi, inventor of Avemar fer...ease issued on November 17 by Biropharma Kft, disc...d self-serving statements about its U.S. competito...from his office in Budapest, Hungary: ,, "The ...apply to AveULTRA, www.aveultra.com , is mislea...
(Date:11/19/2009)...wire-FirstCall/ -- Spherix Incorporated (Nasdaq: ... therapy, and a provider of technical and regulato...hnology and pharmaceutical companies, today announ...reholders. ,, At the meeting, shareholders of S...ollowing members to the Board of Directors: ,, ...
(Date:11/19/2009)... - Aegera Therapeutics Inc. announced today the do... study of AEG35156, a targeted antisense therapeut...indications. ,, The study, entitled "An Open-La...itor of Apoptosis (XIAP) Antisense AEG35156 Given ...bicin in AML Following Failure of a Single Standar...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
... of potential vaccine for low-resource countries ,...e biotech company Lentigen Corporation and the non...oday a partnership to accelerate research on a pan...t $3 million over 27 months and work with Lentigen...article (VLP) prototype pandemic influenza vaccine...
...E Alternext US: NBS), which is pioneering the pre-...e of adult stem cells for future medical need,toda...in its current business,plan with the opening of t...adult stem cells by the general public for future ... Yaffe, M.D., Yaffe, Ruden and Associates (founder...
...ar-old,prostate cancer patient from Montpellier ha...using RapidArc(TM) technology from Varian Medical ...of intensity modulated radiotherapy,(IMRT). Each o...Lamarque in,the city took just 75 seconds, several...r. Pascal Fenoglietto, the hospital,s chief medica...
Other Biology Technology:Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 2Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 4Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3
(Date:11/20/2009)...t published in the November 2009 issue of the jour...ists show how a family of genes (1-aminocyclopropa...nsible for production of ethylene. This gas affect...rmation lays the foundation for future genetic man..., able to survive and thrive in difficult terrain,...
(Date:11/20/2009)...e measurements of plasma lipoprotein concentration...scopy (NMR), researchers led by Daniel Chasman at ...chool in Boston, MA, the Framingham Heart Study in...holm, Sweden and Oxford, England performed genetic...g 17,296 women of European ancestry from the Women...
(Date:11/20/2009)...ited to contribute their abstracts to the World Co...e largest global meeting devoted to all aspects of...ent care. The Congress will be held in Florence, I...racts can be submitted online at http://www.iofwc...ruary 4, 2010. , IOF and ESCEO are pleased to an...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2Genetic analysis helps dissect molecular basis of cardiovascular disease 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Anthem Life offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with the Loss of a Loved One 56223 1Anthem Life offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with the Loss of a Loved One 56223 2Visit AARPs Kernels for Healthcare Reform and Cast Your Vote 56220 1Visit AARPs Kernels for Healthcare Reform and Cast Your Vote 56220 2Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 13852 1
... the new study, the presence of caspase-12, which ...ty in humans, increases the body,s "vulnerability ...eficiency confers strong resistance to sepsis. Thi...ts could be a potentially useful in the treatment ...ers. , The study was published in the April 20 ed...
...at Harvard Medical School (HMS) report in the Apri...rons that encode the values that subjects assign t...ight facilitate the process of decision-making tha...ods. , "We have long known that different neurons ...attributes, such as quantity, color, and taste. Bu...
...from Rensselaer Polytechnic Institute and the Univ...ly of molecules that successfully counteracts and ...periments. The novel approach used to neutralize a...therapeutics for a variety of pathogens and toxins...ecreted by the anthrax bacterium, is made of prote...
Other Biology News:Lack of a key enzyme dramatically increases resistance to sepsis 2Lack of a key enzyme dramatically increases resistance to sepsis 3Attention shoppers: Researchers find neurons that encode the value of different goods 2Attention shoppers: Researchers find neurons that encode the value of different goods 3Anthrax inhibitor counteracts toxin, may lead to new therapeutics 2Anthrax inhibitor counteracts toxin, may lead to new therapeutics 3
Peptide Antibody from Proteintech Group, Inc.
Bovine Albumin from Bovine Serum, Texas Red conjugated/tagged from Molecular Probes (Invitrogen)
Essential Techniques: Antibody Production from Promega
Dynabeads Epithelial Enrich from Dynal Biotech
Biology Products: